Tag Archive: angiotensin receptor-neprilysin inhibitor (ARNI)

Jul 22

Treating HFrEF with sacubitril/valsartan reduces all-cause and heart-failure readmissions

Findings based on data from the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial show that treating patients with heart failure and reduced ejection fraction (HFrEF) with the angiotensin receptor-neprilysin inhibitor (ARNI) sacubitril/valsartan (Entresto, Novartis) led to a 26% lower rate of 30-day …

Continue reading »